Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Lung Cancer

Free Subscription 06.07.2026 3 Ann Surg Oncol 4 Anticancer Res 26 BMC Cancer 3 Br J Cancer 3 Cancer Chemother Pharmacol 2 Cancer Epidemiol Biomarkers Prev 2 Cancer Lett 2 Chest 4 Clin Cancer Res 8 Clin Lung Cancer 1 Clin Nucl Med 3 Eur J Cancer 1 Int J Cancer 1 Int J Oncol 3 J Cancer Res Clin Oncol 2 J Clin Invest 1 J Clin Oncol 1 J Nucl Med 2 J Thorac Cardiovasc Surg 10 J Thorac Oncol 2 Lancet Oncol 9 Lung Cancer 1 Mol Cancer Ther 1 Nat Med 1 Oncogene 1 Oncologist 1 PLoS One 1 Proc Natl Acad Sci U S A 1 Science 1 Thorax

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Surg Oncol

1. NAEEM W, Khan AA, Broad S, Chandramouli S, et al
   Survival of Squamous Cell Carcinoma Versus Adenocarcinoma in Resected Stage I-III Non-small Cell Lung Cancer.
   Ann Surg Oncol. 2026 Jul 3. doi: 10.1245/s10434-026-20070.
   PubMed         Abstract available
   
   
2. KANZAKI R, Okami J, Tokunaga T, Iwasaki T, et al
   Long-term Outcomes of Surgery for Clinical T4 Non-Small Cell Lung Cancer: Implications for Surgical Decision Making in the TNM 9th Edition Era.
   Ann Surg Oncol. 2026 Jun 29. doi: 10.1245/s10434-026-19961.
   PubMed         Abstract available
   
   
3. TANE S, Maniwa Y
   ASO Author Reflections: Preoperative Clues to Complex Surgery After Neoadjuvant Immunochemotherapy in Non-Small-Cell Lung Cancer.
   Ann Surg Oncol. 2026 Jun 27. doi: 10.1245/s10434-026-20083.
   PubMed        
   
   

   
   Anticancer Res

4. IMPROTA G, Vita G, Tartarone A, Calice G, et al
   CTNNB1 Mutations in Non-small Cell Lung Cancer: Clinicopathological Characteristics of a Small Cohort.
   Anticancer Res. 2026;46:3699-3707.
   PubMed         Abstract available
   
   
5. KUBO S, Somekawa K, Nagaoka S, Matsumoto S, et al
   Nab-paclitaxel or Paclitaxel Treatment for Relapsed Small Cell Lung Cancer: A Single-arm Meta-analysis.
   Anticancer Res. 2026;46:4119-4128.
   PubMed         Abstract available
   
   
6. STREUBEL MK, Doehring L, Grauslund HF, Kristiansen C, et al
   Physical Activity During Radiotherapy for Lung Cancer - Evaluating Functionality and Practicability of a Reminder App in Healthy Volunteers.
   Anticancer Res. 2026;46:4129-4137.
   PubMed         Abstract available
   
   
7. BASMAJIAN K, Stepanyan Z, Sarkissian S
   A Systematic Review and Meta-analysis of Clinical Trials in ALK-positive Non-small Cell Lung Cancer.
   Anticancer Res. 2026;46:3609-3618.
   PubMed         Abstract available
   
   

   
   BMC Cancer

8. AGELAKI S, Demiri S, Kotsakis A, Mauri D, et al
   Epidemiological trends of non-small cell lung cancer and systemic treatment rates as part of initial therapeutic strategy from 2016 to 2020 in Greece: results of the epidemiological part of INFINITY study.
   BMC Cancer. 2026 Jul 3. doi: 10.1186/s12885-026-16441.
   PubMed         Abstract available
   
   
9. AOKI Y, Kaseda K, Nishida R, Okubo Y, et al
   Clinical outcomes of percutaneous cryoablation for pulmonary metastases of soft tissue and bone sarcomas under local anesthesia: a single-institution retrospective cohort study.
   BMC Cancer. 2026 Jul 2. doi: 10.1186/s12885-026-16380.
   PubMed         Abstract available
   
   
10. NIE Y, Liang D, Jin Y, Gao M, et al
    Reproductive factors and lung cancer risk in never-smoking women: a prospective cohort study.
    BMC Cancer. 2026 Jun 29. doi: 10.1186/s12885-026-16429.
    PubMed         Abstract available
    
    
11. JIA Z, Yang C, Gao K
    Analysis of chemoimmunotherapy and inflammatory indices in stage III unresectable lung squamous cell carcinoma.
    BMC Cancer. 2026;26:800.
    PubMed         Abstract available
    
    
12. BORG M, Farver-Vestergaard I, Hilberg O, Steed L, et al
    Long-term risk of depression in lung, colon, breast, and prostate cancer: a 25-year nationwide comparative study.
    BMC Cancer. 2026 Apr 28. doi: 10.1186/s12885-026-16095.
    PubMed        
    
    
13. MURRELL DH, Andratschke N, Bergman AM, Brock K, et al
    Re-evaluating previous dose and allowing increasing recovery (REPAIR): study protocol for a thoracic reirradiation phase I dose escalation trial.
    BMC Cancer. 2026;26:724.
    PubMed         Abstract available
    
    
14. SHAFIE RE, Willmann J, Gkika E, Schimek-Jasch T, et al
    FDG-PET/CT based small volume accelerated immuno chemoradiotherapy in locally advanced NSCLC (PACCELIO) - a randomized, open-label, multicenter phase II trial protocol.
    BMC Cancer. 2026;26:494.
    PubMed         Abstract available
    
    
15. TIAN H, Cheng Y, Li D, Du R, et al
    Application of percutaneous cryoablation for pulmonary nodules and influence in pulmonary function.
    BMC Cancer. 2026;26:803.
    PubMed         Abstract available
    
    
16. WU L, Xie T, Li Y, Hao X, et al
    Biomarker exploration for immunotherapy plus chemotherapy following resistance to third-generation EGFR-TKIs in lung adenocarcinoma.
    BMC Cancer. 2026;26:660.
    PubMed         Abstract available
    
    
17. AVILES-SALAS A, Dupont DD, Aranda-Gutierrez A, Heredia-Jara AN, et al
    Clinical, diagnostic and prognostic relevance of GATA3 in malignant pleural mesothelioma: a retrospective cohort study.
    BMC Cancer. 2026;26:436.
    PubMed         Abstract available
    
    
18. WANG Z, Cao Y, Wang Q, Wang L, et al
    Real-world evidence for first-line intrathecal pemetrexed in leptomeningeal metastases from solid tumors: a retrospective cohort study.
    BMC Cancer. 2026;26:651.
    PubMed         Abstract available
    
    
19. SHAO W, Gu W, Song S, Chen D, et al
    Deep learning framework for predicting EGFR mutation status from H&E whole slide images in lung adenocarcinoma.
    BMC Cancer. 2026;26:601.
    PubMed         Abstract available
    
    
20. ZHAO M, Li J, Jiang Y, Shao H, et al
    Optimizing treatment and sequencing strategies for maximal survival and net health benefits in ALK-positive NSCLC: a systematic review and reconstructed individual patient data meta-analysis.
    BMC Cancer. 2026;26:629.
    PubMed         Abstract available
    
    
21. SOBEIH ME, Helal M, Yahia M, Khorshid O, et al
    Gemcitabine as maintenance treatment of diffuse pleural mesothelioma: randomized phase II study.
    BMC Cancer. 2026;26:458.
    PubMed         Abstract available
    
    
22. LIU S, Yi H, Zhou X, Wang X, et al
    Safety evaluation of PD-1/PD-L1 therapies for treatment of NSCLC: a systematic review, bayesian network meta-analysis, and cost-effectiveness analysis.
    BMC Cancer. 2026;26:566.
    PubMed         Abstract available
    
    
23. ZHANG C, Deng R, Zhang W, Liu Z, et al
    EGFR G719X + S768I co-mutations in NSCLC: genomic landscape and differential responses to EGFR-TKIs in a large real-world cohort.
    BMC Cancer. 2026;26:550.
    PubMed         Abstract available
    
    
24. XIE J, Che S, Li J, Niu Y, et al
    Differential diagnosis of benign lesions and lung adenocarcinoma presenting as lung-RADS 2022 category 4B solid nodules based on multiscale CT radiomics.
    BMC Cancer. 2026;26:561.
    PubMed         Abstract available
    
    
25. CAGLAR AA, Hannarici Z, Buyukbayram ME, Turhan A, et al
    Distinguishing adrenal metastases from benign lesions in NSCLC: the value of clinical and radiological parameters.
    BMC Cancer. 2026;26:532.
    PubMed         Abstract available
    
    
26. CUI W, Li Y, Hu M, Zhang TT, et al
    Lipopolysaccharide suppresses lung metastasis by activating CD8(+) T cells despite promoting effect via cancer-associated fibroblasts.
    BMC Cancer. 2026;26:498.
    PubMed         Abstract available
    
    
27. LI S, Huang M, Jia L, Liu S, et al
    In silico design of the multi-epitope vaccine for lung adenocarcinoma based on hub gene-derived neoantigens.
    BMC Cancer. 2026;26:476.
    PubMed         Abstract available
    
    
28. HUANG Y, Zhu G, Yang H, Zhang Y, et al
    Long-read sequencing and proteomics reveal blood transcriptome and protein expression profiles in multiple primary lung cancers.
    BMC Cancer. 2026;26:444.
    PubMed         Abstract available
    
    
29. SARAY S, Engin B, Kadioglu A, Akin M, et al
    Radiotherapy improves outcomes in patients with NSCLC receiving nivolumab.
    BMC Cancer. 2026;26:339.
    PubMed         Abstract available
    
    
30. ESSA MEA, Noori H, Butler J, Ahmed AA, et al
    Gut microbial signatures and immunotherapy outcomes in NSCLC and melanoma: a systematic review and meta-analysis.
    BMC Cancer. 2026 Feb 21. doi: 10.1186/s12885-026-15763.
    PubMed        
    
    
31. REN J, Zeng H, Zhang G, Ren F, et al
    Integrated analysis reveals GSTA1 as a prognostic biomarker in stage I lung adenocarcinoma.
    BMC Cancer. 2026;26:356.
    PubMed         Abstract available
    
    
32. DING J, Cheng G, Xue Q, Guo W, et al
    Mitochondrial DNA methylation predicts immunotherapy response and prognosis in lung adenocarcinoma: evidence from scRNA-Seq and machine learning.
    BMC Cancer. 2026;26:359.
    PubMed         Abstract available
    
    
33. LIAO R, Zhang Y, Li G
    Construction and validation of a recurrence prediction model for lung adenocarcinoma after treatment integrating radiomics features and clinical indicators.
    BMC Cancer. 2025;26:103.
    PubMed         Abstract available
    
    

    
    Br J Cancer

34. LI Q, Yuan H, Li L, Zhao G, et al
    Altretamine induces ferroptosis in small cell lung cancer by promoting epigenetic silencing and lysosomal degradation of GPX4.
    Br J Cancer. 2026 Jul 2. doi: 10.1038/s41416-026-03531.
    PubMed         Abstract available
    
    
35. NAVARATNAM S
    Can national lung cancer screening programs be implemented without exacerbating social disparities?
    Br J Cancer. 2026 Jun 30. doi: 10.1038/s41416-026-03525.
    PubMed         Abstract available
    
    
36. CHEN F, Chen Y, Sun W, Ma H, et al
    Anti-PDGFRalpha autoantibody - a novel diagnostic and prognostic marker - may mediate non-small cell lung cancer progression via the PI3K/AKT/NF-kappaB signaling pathway.
    Br J Cancer. 2026 Jun 27. doi: 10.1038/s41416-026-03501.
    PubMed         Abstract available
    
    

    
    Cancer Chemother Pharmacol

37. NAKAJO M, Uchino T, Asada K, Hatta I, et al
    Composition and structure of stratum corneum intercellular lipids in patients with osimertinib-induced hand-foot syndrome.
    Cancer Chemother Pharmacol. 2026;96:68.
    PubMed         Abstract available
    
    
38. BHARATH P, Iyer S, Velu AV, Kumar DT, et al
    ALK rearrangements and resistance mutations in non-small cell lung cancer: molecular mechanisms and therapeutic implications.
    Cancer Chemother Pharmacol. 2026;96:66.
    PubMed         Abstract available
    
    
39. ALAMILLA-GARCIA G, Tahuahua-Flores O, Soriano-Maya A, Caballe-Perez E, et al
    Durable response to brigatinib in a ROS1 fusion-positive inflammatory myofibroblastic tumor.
    Cancer Chemother Pharmacol. 2026;96:37.
    PubMed         Abstract available
    
    

    
    Cancer Epidemiol Biomarkers Prev

40. BALLESTEROS J, Ikenouchi A, Choi SY, Clark A, et al
    Preferences for Blood-Based Versus Traditional Screening Modalities for Lung and Colorectal Cancers: Insights from a Conjoint Analysis Among US Adults.
    Cancer Epidemiol Biomarkers Prev. 2026;35:1197-1207.
    PubMed         Abstract available
    
    
41. YAU STY, Hung CT, Leung EYM, Lee A, et al
    Association between Statin Use and the Risk of Colorectal, Liver, and Lung Cancers: A Population-Based Retrospective Cohort Study.
    Cancer Epidemiol Biomarkers Prev. 2026;35:1189-1196.
    PubMed         Abstract available
    
    

    
    Cancer Lett

42. WU S, Li S, Zheng Y, Zhang L, et al
    Immunotherapy-based combination remodels the immunosuppressive microenvironment and enhances efficacy in advanced SMARCA4-deficient non-small cell lung cancer.
    Cancer Lett. 2026 Jul 3:218702. doi: 10.1016/j.canlet.2026.218702.
    PubMed         Abstract available
    
    
43. WANG YZ, Wang YG, Pan Y, Gang XY, et al
    Early-onset lung cancer: etiologic heterogeneity, genomic features, and age-informed clinical management.
    Cancer Lett. 2026 Jul 2:218703. doi: 10.1016/j.canlet.2026.218703.
    PubMed         Abstract available
    
    

    
    Chest

44. LIU H, Yan S, Liu P, Zhang C, et al
    Lung Cancer Incidence and Mortality after Negative Low-Dose CT Screening Results.
    Chest. 2026 Jul 1:S0012-3692(26)00936-0. doi: 10.1016/j.chest.2026.
    PubMed         Abstract available
    
    
45. MULLIN ML, Creamer AW, Bhamani A, Verghese P, et al
    Symptom prevalence and impact on lung cancer risk in the SUMMIT study.
    Chest. 2026 Jun 30:S0012-3692(26)00918-9. doi: 10.1016/j.chest.2026.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

46. MARINELLO A, Rotow JK, Lomibao M, Miliziano D, et al
    Retreatment with First-Generation Selective RET Inhibitors in RET-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib: Results from the RET-MAP Registry.
    Clin Cancer Res. 2026;32:2637-2643.
    PubMed         Abstract available
    
    
47. ANDERS P, Sextro M, Lingelbach K, Standvoss K, et al
    ADC Target Profiling in NSCLC: Generalizable AI Separates TROP-2 and cMET Phenotypes.
    Clin Cancer Res. 2026;32:2765-2786.
    PubMed         Abstract available
    
    
48. GARRALDA E, Markert C, Moreno V, Calvo E, et al
    A first-in-human phase 1 clinical trial evaluating clinical activity and proof-of-mechanism of tobemstomig, a PD1-LAG3 bispecific antibody, in patients with CPI-experienced melanoma.
    Clin Cancer Res. 2026 Apr 7. doi: 10.1158/1078-0432.CCR-25-4478.
    PubMed         Abstract available
    
    
49. VISTA WR, Malik V, Sheehan MC, Ismail J, et al
    Irreversible Electroporation Enhances Solid Tumor Infiltration and Selective Cancer Cell Lysis by CAR T Cells.
    Clin Cancer Res. 2026;32:2708-2721.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

50. DI Y, Pang H, Wang X, Meng L, et al
    Pretreatment SUVmax Stratifies the Benefit of Consecutive Daily SBRT in Early-Stage Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2026;27:75-82.
    PubMed         Abstract available
    
    
51. SHAH R, Buchmeier EL, Kopp HG, Griesinger F, et al
    Outcomes of Platinum Plus Pemetrexed and Treatment Patterns Following First-Line Nivolumab and Ipilimumab in Pleural Mesothelioma: Real-World Results From the German MesoNet Study.
    Clin Lung Cancer. 2026;27:68-74.
    PubMed         Abstract available
    
    
52. LIU Y, Qi Y, Pan W, Bai W, et al
    Dosimetric Predictors of Radiation Pneumonitis for Stage III NSCLC Treated With Neoadjuvant Immuno-chemotherapy and Definitive Chemoradiation: A Multi-institutional Analysis.
    Clin Lung Cancer. 2026;27:50-57.
    PubMed         Abstract available
    
    
53. TAKEDA K, Yamamoto T, Umezawa R, Takahashi N, et al
    Durvalumab After Chemoradiotherapy for Locally Advanced NSCLC: A Real-World Analysis Using a Nationwide Claims Database in Japan.
    Clin Lung Cancer. 2026;27:43-49.
    PubMed         Abstract available
    
    
54. HAYASHI N, Suzawa K, Nishimura MF, Yamamoto H, et al
    Radiological Predictors of Visceral Pleural Invasion in Lung Cancers With Ground-Glass Opacity and Pleural Contact.
    Clin Lung Cancer. 2026;27:36-42.
    PubMed         Abstract available
    
    
55. PASELLO G, Scattolin D, Faccioli E, Zucali PA, et al
    CHIMERA: A Phase II Study of Neoadjuvant Pembrolizumab in Combination With Cisplatin or Carboplatin and Pemetrexed Followed by Surgery and Adjuvant Pembrolizumab in Resectable Pleural Mesothelioma.
    Clin Lung Cancer. 2026;27:31-35.
    PubMed         Abstract available
    
    
56. MAMEDE I, Taylor S, Nohmi RL, Riya IJ, et al
    Neoadjuvant Chemoimmunotherapy in Resectable NSCLC With PD-L1 Expression < 1%: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Clin Lung Cancer. 2026;27:19-26.
    PubMed         Abstract available
    
    
57. BOUTAHIR A, Bouazzi L, Barbe C, Deslee G, et al
    Clinical and Functional Factors Associated With Radiation Pneumonitis After Stereotactic Body Radiation Therapy for Lung Tumors: A Retrospective Cohort Study.
    Clin Lung Cancer. 2026;27:83-90.
    PubMed         Abstract available
    
    

    
    Clin Nucl Med

58. SABER TANHA A, Askari E, Moeini Nodeh M, Aghaee A, et al
    99mTc?FAPI?46 Scintigraphy for Staging of Non-Small Cell Lung Carcinoma.
    Clin Nucl Med. 2026 Jun 29. doi: 10.1097/RLU.0000000000006539.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

59. WALSTRA ANH, Heuvelmans MA, Han D, Hubert J, et al
    Clinical urgency of incidental findings in the first year of the 4-IN-THE-LUNG-RUN lung cancer screening program.
    Eur J Cancer. 2026;244:116909.
    PubMed         Abstract available
    
    
60. MARWITZ S, Brunnstrom H, Gulyas M, Botling J, et al
    Left behind but not left alone: Excluded cell populations in the non-small cell lung cancer stroma predict superior long-term overall survival.
    Eur J Cancer. 2026;244:116868.
    PubMed         Abstract available
    
    
61. LEONETTI A, Perrone F, Puntoni M, Maglietta G, et al
    Corrigendum to "Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed" [Eur J Cancer 202, May 2024, 114006].
    Eur J Cancer. 2026;244:116901.
    PubMed        
    
    

    
    Int J Cancer

62. FANG J, Wang Z, Wang H, Xue J, et al
    High Endothelial Venules in Small Cell Lung Cancer: Prognostic Subtypes and Therapeutic Implications for Immunoradiotherapy.
    Int J Cancer. 2026 Jul 3. doi: 10.1002/ijc.70639.
    PubMed         Abstract available
    
    

    
    Int J Oncol

63. CHUANG TH, Guo JH, Yang JX, Tseng JC, et al
    PDLIM2 acts as a central regulator of ubiquitination, immune signaling, and mitochondrial metabolism in lung cancer suppression (Review).
    Int J Oncol. 2026;69:96.
    PubMed         Abstract available
    
    

    
    J Cancer Res Clin Oncol

64. ZHOU W, Song M, Song J, You L, et al
    Predictive value of folate receptor-positive circulating tumor cells in postoperative progressive disease of non-small cell lung cancer patients.
    J Cancer Res Clin Oncol. 2026 Jun 28. doi: 10.1007/s00432-026-06554.
    PubMed         Abstract available
    
    
65. DUAN H, Xie MY, Chen LH, Luo BT, et al
    Epithelial-myoepithelial carcinoma of the lung: a case report and literature review.
    J Cancer Res Clin Oncol. 2026;152:98.
    PubMed         Abstract available
    
    
66. XUE L, Yao J, Xu Q, Geng Y, et al
    The efficacy and toxicity of TRT on metastatic NSCLC in patients treated with targeted therapy and chemoimmunotherapy.
    J Cancer Res Clin Oncol. 2026;152:86.
    PubMed         Abstract available
    
    

    
    J Clin Invest

67. HO R, Mills JC
    Cellular plasticity as a therapeutic vulnerability: HNF4alpha is a key target in lung adenocarcinoma.
    J Clin Invest. 2026;136:e207473.
    PubMed         Abstract available
    
    
68. ESSEL DADZIE H, Green YS, Camolotto SA, Arnold HU, et al
    HNF4alpha controls growth, identity, and KRAS inhibitor response in invasive mucinous adenocarcinoma of the lung.
    J Clin Invest. 2026;136:e198282.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

69. PURI S, Ismaila N, Azar IH, Freeman-Daily J, et al
    Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2.
    J Clin Oncol. 2026 Jun 29:101200JCO2601479. doi: 10.1200/JCO-26-01479.
    PubMed         Abstract available
    
    

    
    J Nucl Med

70. DUAN S, Tan B, Mao Y, Zhang Y, et al
    ICOS-Targeted Peptide Imaging Informs Therapeutic Response of STING Agonist in Lung Adenocarcinoma.
    J Nucl Med. 2026;67:1062-1069.
    PubMed         Abstract available
    
    

    
    J Thorac Cardiovasc Surg

71. YANG Z, Wang S, Ni J, Yu X, et al
    Surgery versus definitive radiotherapy after induction immunochemotherapy for stage II and III non-small cell lung cancer: A multicenter, pragmatic analysis.
    J Thorac Cardiovasc Surg. 2026;172:11-23.
    PubMed         Abstract available
    
    
72. PAN Y, Sun C, Xu H, Jin X, et al
    Pathologic response and nodal status guide adjuvant immunotherapy in non-small cell lung cancer after neoadjuvant chemoimmunotherapy: An eastern Asian cohort study.
    J Thorac Cardiovasc Surg. 2026;172:1-10.
    PubMed         Abstract available
    
    

    
    J Thorac Oncol

73. ALLGAUER M, Kluck K, Kazdal D, Budczies J, et al
    A Response to the Letter to the Editor: Population-informed Assessment of Clonality in Lung Cancer.
    J Thorac Oncol. 2026;21:103725.
    PubMed        
    
    
74. SETHAKORN N, Chiang AC
    Leveraging Vulnerabilities of Molecular Subtypes to Identify Rational Combination Therapies-The Next Wave in Extensive-Stage SCLC?
    J Thorac Oncol. 2026;21:103898.
    PubMed         Abstract available
    
    
75. INAMURA K, Oka A, Todo S, Muto-Ishizuka M, et al
    Methodological Considerations in Bioinformatics-Based Staging of Multifocal Lung Cancer.
    J Thorac Oncol. 2026;21:103684.
    PubMed        
    
    
76. RYAN DT, Shah R, Ridge CA
    Interventional Radiology and Thoracic Oncology: 20 Years of Innovation.
    J Thorac Oncol. 2026;21:103890.
    PubMed         Abstract available
    
    
77. SALLE FG, Beasley MB, Brcic L, Cooper W, et al
    Update on Pleural Epithelioid Mesothelioma: New Insights for Diagnosis and Patient Management.
    J Thorac Oncol. 2026;21:103720.
    PubMed         Abstract available
    
    
78. SAW SPL, Li MSC, Park S, Hatano H, et al
    Targeting MET in EGFR-Mutated NSCLC.
    J Thorac Oncol. 2026;21:103711.
    PubMed         Abstract available
    
    
79. LEVY B, Paz-Ares L, Lin CC, Herbert S, et al
    Datopotamab Deruxtecan Plus Pembrolizumab With or Without Platinum-Based Chemotherapy for Advanced or Metastatic NSCLC: The Phase Ib TROPION-Lung02 Trial.
    J Thorac Oncol. 2026;21:103688.
    PubMed         Abstract available
    
    
80. TORASAWA M, Shukuya T, Huang J, Nagai R, et al
    Tumor Inflammation-Associated Neurotoxicity Masquerading as Severe Immune Effector Cell-Associated Neurotoxicity Syndrome in a Patient With SCLC Treated With Tarlatamab: A Case Report.
    J Thorac Oncol. 2026;21:103649.
    PubMed         Abstract available
    
    
81. BOOTH A, Hillman S, Laumann K, Zhao YQ, et al
    PROSPECT-LUNG: A National Clinical Trials Network Trial Advancing Pragmatic Innovation in Cancer Clinical Trials.
    J Thorac Oncol. 2026;21:103650.
    PubMed         Abstract available
    
    
82. DI FEDERICO A, Hong L, Elkrief A, Thummalapalli R, et al
    TTF-1 Expression in Lung Adenocarcinoma: Clinicopathologic, Genomic, and Immunophenotypic Correlates and Outcomes to Immunotherapy-Based Treatments and KRAS(G12C) Inhibitors.
    J Thorac Oncol. 2026;21:103610.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

83. BRUNETTI L, Santo V, Pinato DJ, Citarella F, et al
    Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial.
    Lancet Oncol. 2026 Jul 3:S1470-2045(26)00191.
    PubMed         Abstract available
    
    
84. LIPMAN KBWG, Wittenberg R, de Oliveira Taveira M, Smesseim I, et al
    Development and validation of artificial intelligence-assisted volumetric response criteria in pleural mesothelioma (ARTIMES): a retrospective, multicohort, multicentre study.
    Lancet Oncol. 2026;27:879-892.
    PubMed         Abstract available
    
    

    
    Lung Cancer

85. LULA LJ, Costa R, Huang L, Rushwan A, et al
    Corrigendum to "European experience on oncological outcomes of patients with early stage non-small cell lung cancer and any prior cancer following lobectomy or segmentectomy" [Lung Cancer J. 217 (2026) 109410].
    Lung Cancer. 2026 Jul 1:109511. doi: 10.1016/j.lungcan.2026.109511.
    PubMed        
    
    
86. COURAUD S, Grolleau E, Letreut J, Rizzo C, et al
    Proportion of lung cancer patients eligible for screening in France: Data from the KBP-2020-CPHG study.
    Lung Cancer. 2026;218:109498.
    PubMed         Abstract available
    
    
87. RADONIC T, Rahmani-Khajouei S, Dafni U, Stenzinger A, et al
    Prevalence and characteristics of NTRK fusions in 25,946 patients with non-small cell lung cancer.
    Lung Cancer. 2026;218:109514.
    PubMed         Abstract available
    
    
88. DAN A, Tendler S, Wagenius G, Viktorsson K, et al
    Prognostic impact of the 9th vs 8th TNM classification in small-cell lung cancer. a population-based study.
    Lung Cancer. 2026;218:109515.
    PubMed         Abstract available
    
    
89. LULA LJ, Costa R, Huang L, Rushwan A, et al
    Corrigendum to "European experience on oncological outcomes of patients with early-stage non-small cell lung cancer and any prior cancer following lobectomy or segmentectomy" Published in [Lung Cancer https://doi.org/10.1016/j.lungcan.2026.109410].
    Lung Cancer. 2026 Jun 30:109508. doi: 10.1016/j.lungcan.2026.109508.
    PubMed        
    
    
90. GALLAGHER TJ, Kokot NC, Kim AW
    Cannabis use disorder and lung cancer risk: methodological considerations in interpretation - Reply to Letter to Editor.
    Lung Cancer. 2026;218:109513.
    PubMed        
    
    
91. HUBERT J, Moldovanu D, van den Bosch I, Katzke V, et al
    Recruitment strategies for lung cancer screening; a randomised trial in the 4-IN-THE-LUNG-RUN study.
    Lung Cancer. 2026;218:109509.
    PubMed         Abstract available
    
    
92. LEE K, Kang M, Namgung Y, Park IH, et al
    Treatment-free survival after two-year immune checkpoint inhibitor treatment in non-small cell lung cancer: Utilizing the Korean Health Insurance Review and Assessment Service database.
    Lung Cancer. 2026;218:109490.
    PubMed         Abstract available
    
    
93. HOFMAN V, Rignol G, Mograbi B, Ilie M, et al
    New biomarkers for antibody-drug conjugates in lung cancer the pathologist's perspective.
    Lung Cancer. 2026;218:109507.
    PubMed         Abstract available
    
    

    
    Mol Cancer Ther

94. SAVOCA A, Zindel D, Polanski R, Kostomiris DH, et al
    Preclinical to Clinical Translation of Pharmacokinetic-Pharmacodynamic Relationship in EGFR Exon20Ins Mutations: A Modeling Framework for Irreversible Inhibitors.
    Mol Cancer Ther. 2026;25:1157-1167.
    PubMed         Abstract available
    
    

    
    Nat Med

95. BYERS LA, Cho BC, Cooper AJ, Chiang AC, et al
    Author Correction: SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.
    Nat Med. 2026 Jun 29. doi: 10.1038/s41591-026-04544.
    PubMed        
    
    

    
    Oncogene

96. LIU Y, Nanjo S, Murase Y, Arai S, et al
    Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer.
    Oncogene. 2026 Jul 2. doi: 10.1038/s41388-026-03877.
    PubMed         Abstract available
    
    

    
    Oncologist

97. MAHMUD S, Dwyer Orr L, Cline M, Mirsalehi A, et al
    Biomarker testing patterns among patients newly diagnosed with metastatic non-small cell lung cancer, prostate cancer, and bladder cancer.
    Oncologist. 2026 Jun 27:oyag243. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    PLoS One

98. YU L, Dong X, Fa K, Li Y, et al
    OncoSeg2D: A deep framework for semantic segmentation of lung cancer in 2D CT scans.
    PLoS One. 2026;21:e0348719.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

99. LIU N, Han G, Zhang F, Gu Q, et al
    TMED9 drives non-small-cell lung cancer progression via promotion of autophagy by recruiting USP5 to deubiquitinate ATG9A.
    Proc Natl Acad Sci U S A. 2026;123:e2532259123.
    PubMed         Abstract available
    
    

    
    Science

100. CROSS M, Kotschi S, Wu W, Luciano-Mateo F, et al
     A dietary switch promotes sensory neuron-dependent cancer-associated cachexia.
     Science. 2026;393:90-97.
     PubMed         Abstract available
     
     

     
     Thorax

101. CHONG AR, Chia JW, Chai CS, Mohd Zain AH, et al
     Mediastinal amyloidosis mimicking advanced lung cancer.
     Thorax. 2026 Jul 2:thorax-2026-225400. doi: 10.1136/thorax-2026-225400.
     PubMed        
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum